Expanded SCAPIS Stockholm re-examination and health profiling
Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination
This follow-up will re-examine former SCAPIS participants aged 50–64 with extra blood, saliva, questionnaires, and imaging to see if these tests help identify risk factors for heart, lung, and liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1400 (estimated) |
| Ages | 56 Years to 74 Years |
| Sex | All |
| Sponsor | Danderyd Hospital Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT07476703 on ClinicalTrials.gov |
What this trial studies
The SCAPIS Stockholm re-examination invites about 2,500 original participants for enhanced clinical, imaging, and biomarker assessments at Danderyd University Hospital and Karolinska Institutet. All participants receive the SCAPIS 2 core exams (blood sampling, questionnaires, imaging) plus complementary local investigations including extended blood cell isolation, saliva sampling, and detailed questionnaires on dyspnea, sleep, respiratory infections, and dental health. Additional imaging and physiological measures include coronary CT angiography, echocardiography and aortic ultrasound, liver elastography, and arterial stiffness measurements. The protocol aims to link imaging, immune profiling, microbiome signals, and clinical data to identify current and future risks for cardiovascular, pulmonary, and liver disease.
Who should consider this trial
Good fit: Ideal candidates are people who previously participated in the SCAPIS Stockholm re-examination (around ages 50–64) and can give informed consent for extra sampling and imaging.
Not a fit: People who were not part of the original SCAPIS cohort or who cannot provide informed consent are not eligible and will not directly benefit from the protocol.
Why it matters
Potential benefit: If successful, this could improve early detection and risk prediction for heart, lung, and liver conditions in middle-aged adults, enabling better-targeted prevention and monitoring.
How similar studies have performed: The original SCAPIS cohort and other large imaging-biomarker cohorts have successfully linked imaging and blood biomarkers to cardiopulmonary risk, although some of the expanded immune and saliva profiling approaches in this protocol are newer and less tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects already included in the main / general SCAPIS reexamination study in Stockholm. Exclusion Criteria: Inability to provide consent.
Where this trial is running
Stockholm
- Cardiovascular Research Lab, Dept Cardiology, Danderyd University Hospital — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Rebecka Hultgren — Karolinska Institutet
- Study coordinator: Jonas Spaak, MD, PhD, Professor
- Email: jonas.spaak@ki.se
- Phone: +4681235500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.